EUVIMEDEUVIMED entdecken
Open Access

Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?

Eugenia Veronica Di Brizzi, Stefano Caccavale, Roberta Di Caprio, Francesco Cusano, Rocco De Pasquale, Valeria Falcomatà, Caterina Foti, Claudia Giofrè, Emanuela Gubinelli, Giampiero Mazzocchetti, Massimiliano Nicolini, Giovanni Palazzo und 4 weitere

Dermatology Practical & Conceptual · 30.10.2024 · 14 (4) · e2024284

DOI: 10.5826/dpc.1404a284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 30.10.2024. Verfasst von Eugenia Veronica Di Brizzi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, University of Campania "L. Vanvitelli". Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown promise in the management of moderate-to-severe plaque psoriasis, offering potential improvements in clinical outcomes and quality of life.

Objectives

The study aimed to identify patient characteristics that indicate the initiation of a 200-mg dosage of tildrakizumab in a real-world setting, focusing on factors that enhance treatment efficacy and safety.

Methods

This prospective study included 54 adult patients with moderate-to-severe plaque psoriasis treated with tildrakizumab 200 mg from March 2023 to March 2024 across 13 Italian Dermatology Units. Data collected included demographics, disease duration, comorbidities, and previous treatments. PASI, BSA, and DLQI scores were recorded at baseline, week 4, 16, and 28. Safety was assessed through adverse event reporting. Univariate analysis was performed to identify baseline characteristics significantly associated with achieving PASI ≤ 5 at week 16.

Results

Significant reductions in PASI scores were observed at week 4 (9 ± 6.9, p

Autor:innen und Institutionen

  • Dermatology Unit, University of Campania "L. Vanvitelli".
  • Department of Dermatology, San Pio Hospital, Benevento, Italy.
  • U.O. Dermatologia, Ospedale San Marco, Catania, Italy.
  • Great Metropolitan Hospital Bianchi Melacrino Morelli, Reggio Calabria, Italy.
  • Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy.
  • U.O.C. Dermatology Unit, "Papardo" Hospital, Messina, Italy.

Zitieren

APA

Di Brizzi, E. V., Caccavale, S., Di Caprio, R., Cusano, F., De Pasquale, R., Falcomatà, V., Foti, C., Giofrè, C., Gubinelli, E., Mazzocchetti, G., Nicolini, M., Palazzo, G., Pescitelli, L., Puca, R. V., Sarno, O., & Balato, A. (2024). Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?. Dermatology Practical & Conceptual, 14(4), e2024284. https://doi.org/10.5826/dpc.1404a284

Vancouver

Di Brizzi EV, Caccavale S, Di Caprio R, Cusano F, De Pasquale R, Falcomatà V, et al. Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?. Dermatology Practical & Conceptual. 2024;14(4):e2024284. doi:10.5826/dpc.1404a284

BibTeX
@article{DiBrizzi2024,
  author = {Di Brizzi, Eugenia Veronica and Caccavale, Stefano and Di Caprio, Roberta and Cusano, Francesco and De Pasquale, Rocco and Falcomatà, Valeria and Foti, Caterina and Giofrè, Claudia and Gubinelli, Emanuela and Mazzocchetti, Giampiero and Nicolini, Massimiliano and Palazzo, Giovanni and Pescitelli, Leonardo and Puca, Rosa Valentina and Sarno, Oriele and Balato, Anna},
  title = {Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?},
  journal = {Dermatology Practical & Conceptual},
  year = {2024},
  volume = {14},
  number = {4},
  pages = {e2024284},
  doi = {10.5826/dpc.1404a284}
}
Kostenlos starten →